On Day 1 of the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium, in San Francisco, CA, IsoPlexis presented new data from a collaboration with Fred Hutch. The poster presentation highlighted that intratumoral (IT) injections of the toll-like receptor 4 (TLR4) agonist G100 induce a clinical response and a T cell response locally and systemically. The ASCO-SITC Clinical Immuno-Oncology Symposium is a three-day meeting which focuses on clinical and translational advances in immuno-oncology, offering new insights on the application of immunotherapy in melanoma, lung cancer, genitourinary cancers, head and neck cancer, and hematologic malignancies.